BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 8474513)

  • 1. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.
    Mandel JS; Bond JH; Church TR; Snover DC; Bradley GM; Schuman LM; Ederer F
    N Engl J Med; 1993 May; 328(19):1365-71. PubMed ID: 8474513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of fecal occult-blood tests for colorectal-cancer screening.
    Allison JE; Tekawa IS; Ransom LJ; Adrain AL
    N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal occult blood testing and the incidence of colorectal cancer.
    Singer RB
    J Insur Med; 2002; 34(2):89-91. PubMed ID: 15305783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Randomized controlled trial of sequence mass screening program for colorectal cancer].
    Liu X; Zheng S; Chen K; Ma X; Zhou L; Yu H; Yao K; Chen K; Cai S; Zhang S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):430-3. PubMed ID: 11860828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients diagnosed with colorectal cancer through a television-advertised screening program.
    Slusser SO; Liberski SM; McGarrity TJ
    Am J Gastroenterol; 1996 Aug; 91(8):1563-6. PubMed ID: 8759662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
    Mandel JS; Church TR; Ederer F; Bond JH
    J Natl Cancer Inst; 1999 Mar; 91(5):434-7. PubMed ID: 10070942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
    Malila N; Oivanen T; Hakama M
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer mortality in two areas of Tuscany with different screening exposures.
    Costantini AS; Martini A; Puliti D; Ciatto S; Castiglione G; Grazzini G; Zappa M
    J Natl Cancer Inst; 2008 Dec; 100(24):1818-21. PubMed ID: 19066268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term mortality after screening for colorectal cancer.
    Shaukat A; Mongin SJ; Geisser MS; Lederle FA; Bond JH; Mandel JS; Church TR
    N Engl J Med; 2013 Sep; 369(12):1106-14. PubMed ID: 24047060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
    Chew MH; Suzanah N; Ho KS; Lim JF; Ooi BS; Tang CL; Eu KW
    Singapore Med J; 2009 Apr; 50(4):348-53. PubMed ID: 19421676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
    Faivre J; Tazi MA; El Mrini T; Lejeune C; Benhamiche AM; Dassonville F
    Br J Cancer; 1999 Feb; 79(3-4):680-3. PubMed ID: 10027349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for colorectal cancer.
    Mandel JS
    Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.